{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:12:03Z","timestamp":1792699923739,"version":"4.5.0"},"reference-count":79,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T00:00:00Z","timestamp":1733529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review the evidence and discuss use of pivmecillinam in uncomplicated acute cystitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources:<\/jats:title>\n                    <jats:p>A literature search was conducted utilizing PubMed (from 2000 through August 2024) and ClinicalTrials.gov. Medical Subject Headings (MeSH) terms, such as mecillinam or pivmecillinam and urinary tract infections, were utilized. Additional references were identified by reviewing literature citations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study selection and data extraction:<\/jats:title>\n                    <jats:p>Articles were limited to English language publications evaluating the efficacy or safety of pivmecillinam for urinary tract infections (UTIs) in adult populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data synthesis:<\/jats:title>\n                    <jats:p>Data from 6 randomized controlled trials support pivmecillinam for acute uncomplicated cystitis at doses of 200 to 400 mg 3 times daily for 3 to 7 days, with more consistent clinical and bacteriologic cure observed with 400 mg doses and longer therapy durations. Clinical evaluation of 400 mg 2 to 3 times daily is available with use more common in non\u2013US Food and Drug Administration (FDA)-approved populations, such as men, pregnancy, and multidrug resistant infections. There are limited data supporting pivmecillinam for pyelonephritis; routine use is cautioned until further clinical data are available.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to patient care and clinical practice in comparison with existing drugs:<\/jats:title>\n                    <jats:p>As resistance to first-line antimicrobials rises, the need for safe and effective treatment options remains high. Pivmecillinam represents a new therapeutic option available in the United States for outpatient management of uncomplicated acute cystitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Pivmecillinam could be a key agent for uncomplicated acute cystitis. Utilization will likely be cost driven, but the promise of low resistance encourages the place in therapy when other agents are not susceptible to infecting uropathogens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280241288554","type":"journal-article","created":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T04:30:01Z","timestamp":1733545801000},"page":"743-757","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Pivmecillinam for Uncomplicated Acute Cystitis: A Contemporary Review"],"prefix":"10.1177","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9838-9985","authenticated-orcid":false,"given":"Jessica E.","family":"Burchette","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, ETSU Bill Gatton College of Pharmacy, East Tennessee State University, Johnson City, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1262-9423","authenticated-orcid":false,"given":"Kelly","family":"Covert","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, ETSU Bill Gatton College of Pharmacy, East Tennessee State University, Johnson City, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4782-1538","authenticated-orcid":false,"given":"Patrick","family":"Tu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, Charlie Norwood Department of Veterans Affairs Medical Center, VA Augusta Health Care, Augusta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan P.","family":"White","sequence":"additional","affiliation":[{"name":"University of Oklahoma Medical Center, Oklahoma City, OK, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4018-0195","authenticated-orcid":false,"given":"Daniel B.","family":"Chastain","sequence":"additional","affiliation":[{"name":"University of Georgia College of Pharmacy, Albany, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3656-1144","authenticated-orcid":false,"given":"David B.","family":"Cluck","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, ETSU Bill Gatton College of Pharmacy, East Tennessee State University, Johnson City, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,12,7]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.15620\/cdc:82532"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlac048"},{"key":"e_1_3_2_4_2","unstructured":"World Health Organization Antibiotic products in clinical development for priority pathogens. Accessed July 13 2024. https:\/\/www.who.int\/observatories\/global-observatory-on-health-research-and-development\/monitoring\/antibacterial-products-in-clinical-development-for-priority-pathogens"},{"key":"e_1_3_2_5_2","volume-title":"WHO Bacterial Priority Pathogens List, 2024: Bacterial Pathogens Of Public Health Importance To Guide Research, Development And Strategies To Prevent And Control Antimicrobial Resistance","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. WHO Bacterial Priority Pathogens List, 2024: Bacterial Pathogens Of Public Health Importance To Guide Research, Development And Strategies To Prevent And Control Antimicrobial Resistance. Licence: CC BY-NC-SA 3.0 IGO.EAU Guidelines. Presented at the EAU Annual Congress Paris 2024. ISBN 978-94-92671-23-3. World Health Organization; 2024."},{"key":"e_1_3_2_6_2","unstructured":"FDA News Release. FDA approves new treatment for uncomplicated urinary tract infections. Released April 24 2024. Accessed July 13 2024. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-uncomplicated-urinary-tract-infections"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01641339PIVYA"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1104429"},{"key":"e_1_3_2_9_2","unstructured":"Center for Drug Evaluation and Research (CDER). Food and Drug Administration. Uncomplicated urinary tract infections: developing drugs for treatment: guidance for industry. Accessed August 26 2024. https:\/\/www.fda.gov\/media\/129531\/download"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq257"},{"key":"e_1_3_2_11_2","unstructured":"PIVYA (pivmecillinam)[packageinsert]. UTILITY Therapeutics Ltd. Published 2024. Accessed August 8 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/216483s000lbl.pdf"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0924-8579(99)00118-1"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002569"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1159\/000221856"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt368"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.suppl_1.9"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp404"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2016.09.006"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1159\/000237814"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2004.00737.x"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.03441-22"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/3.suppl_b.13"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11060751"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2015.05.022"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1155\/2001\/601743"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz211"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2018.11.004"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S209255"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac396"},{"key":"e_1_3_2_30_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). European Society of Clinical Microbiology and Infectious Diseases. Clinical breakpoints. Accessed July 13 2024. https:\/\/www.eucast.org\/clinical_breakpoints"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlac059"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02402-18"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2019.05.012"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2020.10.016"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-015-2498-3"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.627267"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac226"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab401"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg028"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.10.6.872"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens11030356"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.03.014"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab466.1237"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa439.1797"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-1797-3"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics8020057"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/apm.12147"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.suppl_1.35"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/3.suppl_b.121"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.3109\/inf.1979.11.issue-4.04"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1177\/030006058000800202"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007998209110100"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1080\/02813430601183074"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365540110080728"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.12830"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1080\/02813430802535312"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2019.06.009"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ucl.2015.05.004"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365540410021072"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0085889"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2011.0161"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky230"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad402"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt404"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1080\/23744235.2020.1736329"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1080\/02813432.2020.1718301"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211098"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2001.13.3.299"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp017"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.1.170-175.2005"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0924-8579(02)00171-1"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(89)92086-2"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1600-0404.2003.00227.x"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2022.100842"},{"key":"e_1_3_2_75_2","author":"Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing","year":"2024","unstructured":"Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 34th ed. CLSI supplement M100. Clinical and Laboratory Standards Institute; 2024.","journal-title":"Clinical and Laboratory Standards Institute;"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab380"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30121-3"},{"key":"e_1_3_2_78_2","unstructured":"Norwegian Directorate of Health. National professional guideline for the use of antibiotics in primary care [online document] (last technical change 03 January 2024 read 19 June 2024). Published 2012. Accessed July 13 2024. https:\/\/www.helsedirektoratet.no\/retningslinjer\/antibiotika-i-primaerhelsetjenesten"},{"key":"e_1_3_2_79_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S163280"},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-055898"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280241288554","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280241288554","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280241288554","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:13:52Z","timestamp":1777374832000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280241288554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,7]]},"references-count":79,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1177\/10600280241288554"],"URL":"https:\/\/doi.org\/10.1177\/10600280241288554","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,7]]}}}